Active Ingredient History

  • Now
Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy including highly emetogenic chemotherapy.   NCATS

  • SMILES: CN(C(=O)C(C)(C)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C2=CN=C(C=C2C3=C(C)C=CC=C3)N4CCN(C)CC4
  • Mol. Mass: 578.5917
  • ALogP: 6.79
  • ChEMBL Molecule:
More Chemistry
  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Combination drugs

( palonosetron (aloxi), netupitant (Akynzeo) - other name: nepa (300mg netupitant/0.5mg palonosetron) )
2-[3,5-bis(trifluoromethyl)phenyl]-n,2-dimethyl-n-[4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]propanamide | akynzeo | netupitant | netupitant / palonosetron | netupitant / palonosetron hydrochloride | netupitant - palosentron | netupitant, palosentron drug combination | ro 67-3189/000 | ro-673189000


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue